{"id":34623,"date":"2021-06-27T20:34:26","date_gmt":"2021-06-27T18:34:26","guid":{"rendered":"https:\/\/genomtec.com\/?page_id=34623"},"modified":"2026-03-19T11:22:25","modified_gmt":"2026-03-19T10:22:25","slug":"press-releases-news","status":"publish","type":"page","link":"https:\/\/genomtec.com\/en\/press-releases-news\/","title":{"rendered":"Press Releases & News"},"content":{"rendered":"
<\/a>
\n

Press Releases<\/h2> <\/div>\n<\/section>\n\n
\n
\n
\n
\n
\n 2026<\/a>2025<\/a>2024<\/a>2023<\/a>2022<\/a>2021<\/a> <\/div>\n <\/div>\n
\n
\n
<\/div>
\n
March 17 2026<\/div>\n

Genomtec plans to issue shares. The proceeds will be used to support the M&A process and commercialize projects. The company has concluded an investment agreement with a key shareholder.<\/h3>\n
Genomtec S.A. on April 13, 2026, at which the Shareholders will vote on an increase in the Company\u2019s share capital through the issue of up to 2 million new series R shares and up to 204,000 series S shares, excluding pre-emptive rights.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 12 2026<\/div>\n

Genomtec lines up technology trials with potential Asian partners during M&A efforts<\/h3>\n
Genomtec S.A. announced that it has undertaken key preparatory activities related to planned testing of Genomtec diagnostic devices in Asia. These activities are directly related to the ongoing M&A process and are a response to the demand expressed by potential partners in this region.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
July 31 2025<\/div>\n

Genomtec’s Supervisory Board appointed Leroy Huntley to the Company’s Management Board<\/h3>\n
Genomtec S.A. announced the appointment of Mr. Leroy Huntley to the Company’s Management Board on July 30, 2025, with effect from August 1, 2025. Leroy Huntley serves as Chief Technology Officer (CTO) at Genomtec and has been associated with the Company since 2022. His appointment strengthens the Management Board’s competences at a key moment for the Company \u2013 the ongoing M&A process<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
July 14 2025<\/div>\n

Genomtec has the consent of its shareholders to make a contribution of assets to its subsidiaries in order to accelerate the project sale process<\/h3>\n
At the Extraordinary General Meeting of Genomtec SA on July 11, 2025, the Shareholders adopted resolutions on the contribution in kind of tangible and intangible assets related to the Genomtec ID platform and the OncoSNAAT project to the special purpose vehicles GMT ID SA and GMT GENOMICS SA, respectively, in which Genomtec SA holds 100% of shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
April 29 2025<\/div>\n

Genomtec sums up an intense 2024 and announces further development plans<\/h3>\n
Genomtec SA has published a report summarizing its activities in 2024 \u2013 a period of intensive development and strategic activities<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 26 2025<\/div>\n

Genomtec implements changes in organizational structure to accelerate M&A process<\/h3>\n
Genomtec SA has established two special purpose vehicles, GMT ID SA and GMT Genomics SA, in which it holds 100% of the shares. They will receive tangible and intangible assets related to the Genomtec ID platform and the OncoSNAAT project, respectively. Each special purpose vehicle, dedicated to a separate technology segment, can be offered separately to potential buyers, enabling more flexible M&A processes<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 12 2025<\/div>\n

Genomtec to issue shares to Shareholder – 5HT Family Foundation. The company will obtain approximately PLN 11 million from the issue to support the commercialization of projects<\/h3>\n
The shareholders of Genomtec SA at the Extraordinary General Meeting on 12 March 2025 voted on a resolution to increase the Company’s share capital by issuing 1,542,556 new ordinary bearer shares of series P, with the entire exclusion of the subscription rights of the existing shareholders. Genomtec will gain approximately PLN 11 million (gross) from the share issue, which will secure the Company’s financial position for the coming months and will allow for further development of projects and efficient implementation of the M&A process.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 12 2025<\/div>\n

Genomtec to issue shares to raise funds to support commercialization of projects<\/h3>\n
The company’s shareholder – 5HT FR intends to sell 1.3 million existing shares of the company in a public offering and use the entire amount of the funds raised to acquire shares of the new issue.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
January 28 2025<\/div>\n

Genomtec has filed a second patent application for the OncoSNAAT oncology project<\/h3>\n
Genomtec SA, a leading molecular diagnostics company headquartered in Wroc\u0142aw (WSE ticker: GMT), announced today that it has filed a patent application with the British Patent Office for an innovative technology for the diagnosis of single-nucleotide genetic changes. The Company’s strategy includes extending patent protection under the international PCT procedure.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
December 11 2024<\/div>\n

Genomtec Announces Changes in the Company\u2019s Organizational Structure Related to the M&A Process<\/h3>\n
The management board of Genomtec S.A., a leading molecular diagnostics company headquartered in Wroc\u0142aw (Ticker GPW: GMT), has made decisions concerning adjustments to the organizational structure in response to the expectations of potential partners in the M&A process, the development of the OncoSNAAT project, and the food safety diagnostics sector.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
April 22 2024<\/div>\n

Dr. Trevor Hawkins, a distinguished entrepreneur, scientist, and leader with experience in global healthcare companies, has joined the Supervisory Board of Genomtec S.A.<\/h3>\n
Genomtec S.A. announces that the Extraordinary General Meeting of Shareholders of the company appointed Dr. Trevor Hawkins to the Supervisory Board as of April 22, 2024.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 12 2024<\/div>\n

Genomtec strengthens the Supervisory Board with individuals who bring extensive industry and business experience<\/h3>\n
Genomtec S.A. announces that the Extraordinary General Meeting of Shareholders of the company has appointed two new members to the Supervisory Board of the company, effective March 12th, 2024: Gualtiero Garlasco and Beata Turlejska, who will replace Jaros\u0142aw Oleszczuk and Karol Hop.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
October 25 2023<\/div>\n

Genomtec received positive evaluation of Grant in Oncology Diagnostics from the Polish Agency for Enterprise Development (PARP) and the European Funds for a Modern Economy program<\/h3>\n
The Genomtec project, titled “Development of technology and an automatic system for mutation detection in clinical oncology based on lab-on-a-chip solutions and isothermal nucleic acid amplification techniques,” is among 198 applications positively evaluated by PARP in the SMART FENG.01.01-IP.02-001\/23\/2023 action within the European Funds for a Modern Economy program.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 28 2023<\/div>\n

Genomtec S.A. expands its Genomtec ID platform to oncology and has filed a patent application specific to oncology diagnostics<\/h3>\n
Genomtec has successfully completed an expansion of its Genomtec ID platform to the field of oncology diagnostics leading to its submission of a patent protection application for a novel oncologic diagnostic method that it developed. This method involves isothermal amplification of nucleic acids for the detection of genetic variants applicable for oncology diagnostics.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 21 2023<\/div>\n

Genomtec S.A. wants the Shareholders to participate in the benefits of the potential M&A transaction to the largest possible extent<\/h3>\n
The Management Board of Genomtec S.A. has passed a resolution to determine how to distribute funds from a potential technology sale. The Company’s intention is for shareholders to benefit from a potential M&A transaction to the fullest extent possible. As part of its ongoing review of strategic options, Genomtec is working with a transaction advisor, Clairfield Partners LLC, based in New York.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 9 2023<\/div>\n

Genomtec S.A. will debut on the main market of the WSE on February 16<\/h3>\n
Genomtec S.A. will debut on February 16 on the regulated market operated by the WSE. The Management Board of the Warsaw Stock Exchange issued resolutions on the ad-mission to stock exchange trading on the main market of series A, B, C, D, E, F, G, H, J, K shares of the Genomtec shelf and their introduction to trading.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
January 10 2023<\/div>\n

Value of the intellectual property portfolio of Genomtec S.A. estimated at EUR 191.336 million<\/h3>\n
Genomtec S.A. received from the German company Dennemeyer Consulting GmbH a valuation of the Company’s intellectual property portfolio. Accord-ing to the DIN\/ISO 77100 standard adopted by Dennemeyer, covering 9 patents held by Genomtec and 26 patent applications, as well as the conversion of all patent applications into patents, as well as a 14-year protection period for the entire IP (intellectual property) portfolio, the fair value of Genomtec’s intellectual property was estimated at EUR 191.336 million.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
November 30 2022<\/div>\n

Genomtec S.A. signs an agreement with Clairfield Partners LLC to advise on sale of company to industry investor<\/h3>\n
Genomtec has signed an agreement with Clairfield Partners LLC, the New York based member firm of Clairfield International (\u201cClairfield\u201d). The purpose of the agreement is to advise on the process of establishing strategic partnerships, selling licenses and\/or selling all or part of Genomtec\u2019s intellectual property and related technology.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 8 2022<\/div>\n

Genomtec S.A. has launched a review of strategic options and signed an agreement to evaluate the company’s IP portfolio<\/h3>\n
Genomtec S.A. has decided to initiate a review of strategic options. In addition, it has signed an agreement with Dennemeyer & Associates, a global patent law firm to perform an assessment of the value of the Company\u2019s Intellectual Property (IP) portfolio.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 10 2022<\/div>\n

Genomtec S.A. wins a new partner to commercialize the Genomtec\u00ae ID platform in Taiwan (R.O.C.).<\/h3>\n
Genomtec has signed up a new Partner for the commercialization of its flagship Genomtec\u00ae ID genetic testing platform and the Respiratory Panel 5-Plex test. The Partner is appointed by Genomtec S.A. to help with identification and qualification of new local business prospects and opportunities for the Genomtec\u00ae ID platform in Taiwan.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
July 11 2022<\/div>\n

Genomtec appoints new Chief Technology Officer<\/h3>\n
Genomtec has appointed Richard Moore as the new Chief Technology Officer to drive its next generation of products and systems. Richard replaces Jason Reece who announced his intentions to retire.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 27 2022<\/div>\n

Genomtec continues to add distributors for its flagship Genomtec\u00aeID platform product and genetic respiratory tests in Europe<\/h3>\n
Genomtec has secured an additional distributor for its Gentomec\u00aeID portable testing platform and RP5-PLEX panel for detecting respiratory tract infections in Europe by entering into an agreement with ForLab SA. Forlab is the second distributor of the Company’s flagship platform after the Greek company Atropos.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 8 2022<\/div>\n

Genomtec\u00aeID Respiratory Panel 5-Plex (RP5-PLEX) for the detection of respiratory tract infections has received CE-IVD certification as the only solution of its kind in Europe<\/h3>\n
Genomtec has obtained the CE-IVD mark for its flagship solution, the Genomtec\u00aeID Respiratory Panel 5-Plex (RP5-PLEX) diagnostic panel for the detection of pathogens causing respiratory diseases. This is the only diagnostic panel of its kind that simultaneously tests for the presence of as many as 5 viruses and bacteria in the same test and which, thanks to CE-IVD certification, will be available for sale in 27 European Union countries as well as in Iceland, Norway and Liechtenstein.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
April 29 2022<\/div>\n

Genomtec signs distribution agreement for Genomtec\u00aeID in Europe<\/h3>\n
Genomtec has signed an exclusive distribution agreement in Greece for its flagship Genomtec\u00aeID genetic testing platform and the Respiratory Panel 5-plex test. Genomtec’s commercial partner Atropos Ltd., is a specialist distributor of molecular biology solutions with an established market position in Greece. Atropos will start the distribution following the regulatory approval of the Genomtec\u00aeID platform and the test.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 14 2022<\/div>\n

Genomtec begins comparative testing phase of Genomtec\u00aeID<\/h3>\n
Genomtec has started the comparative testing phase of Genomtec\u00aeID, a mobile platform for genetic diagnostics and the Respiratory Panel (RP) 5-plex assay. The results obtained in this clinical study will be the basis for the CE-IVD registration of Genomtec\u00aeID in the European Union planned for the middle of this year.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
January 20 2022<\/div>\n

European Patent Office grants Genomtec with new Patent<\/h3>\n
Genomtec has received a patent from the European Patent Organization (EPO) for the Genomtec\u00aeID technology and device invented by Genomtec SA. The invention under new patent protection includes Genomtec\u00aeID, the Company’s key technology related to a proprietary non-contact heating and temperature sensing system developed for point-of-care testing (POCT) and other applications. This is the first patent granted by EPO and the seventh received by Genomtec. The company has more than twenty patent applications pending worldwide.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
January 12 2022<\/div>\n

Genomtec begins pilot production of Genomtec\u00aeID analyzers<\/h3>\n
Genomtec has begun pilot production of analyzers for the first 15 Genomtec\u00aeID devices. The analysers are being manufactured by the Genomtec team in the UK in close collaboration with the CDMO partner there. The start of production was made possible by the completion of the design and reliability testing of the analyzer components.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
November 30 2021<\/div>\n

Genomtec’s laboratory genetic test detects all variants of SARS-CoV-2 including Omicron<\/h3>\n
Genomtec has conducted an analysis of its rapid genetic tests that confirmed their effectiveness in detecting all known variants of the SARS-CoV-2 virus including the recently discovered Omicron variant.<\/div>
Download<\/a><\/div><\/div>
Genomtec rapid genetic test sensitivity report.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 29 2021<\/div>\n

Genomtec files a new patent application in the UK<\/h3>\n
Genomtec has filed a patent application entitled “Thermal interface arrangement” for a proprietary method of heat transfer and measurement with the UK Intellectual Property Office (UK IPO). The Issuer’s invention may have broad application not only in diagnostics, but also in biomedical solutions, electronics or mechanics.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 25 2021<\/div>\n

Miron Tokarski Awarded with Laureate of “Leaders of the Future” Ranking by Forbes<\/h3>\n
Miron Tokarski, co-founder and CEO of Genomtec, found himself among the honourable laureates of the Forbes Magazine ranking: “Leaders of the Future”, organized by the Range Rover brand. Out of 140 nominated candidates the Chapter selected 10 Leaders, visionaries from various fields of life, who in one, five or ten years will be able to decide about the shape of the world.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 19 2021<\/div>\n

Genomtec receives sixth patent protecting the Company’s technology for HPV-16 genetic diagnostics<\/h3>\n
Genomtec has received patent protection from the Polish Patent Office for a primer set for the detection of Human papillomavirus-16 (HPV16), a method for detecting HPV16 infection, and an application of the primer set for detecting HPV infection.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 8 2021<\/div>\n

Genomtec gets closer to commercializing its Genomtec\u00aeID platform – Q3 2021 summary<\/h3>\n
Genomtec released its Q3 2021 report. Q3 was a period of intensified work on Genomtec\u00aeID – the company obtained 2 additional patents (in total it already holds 5). The patent issued by the Polish Patent Office for the non-contact heating and detection technology now has an expanded scope of being protected in any device or heating systems applicable outside the medical industry in addition to its current use in genetic applications such as Genomtec\u00aeID.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 3 2021<\/div>\n

Genomtec to accelerate commercialization of Genomtec\u00aeID<\/h3>\n
Genomtec started today the analysis to accelerate the planned commercialization of the Genomtec\u00aeID platform. The analysis will include the selection of solutions to support the company’s strategic development, primarily in terms of determining the optimal time to market with the Genomtec\u00aeID solution, including its acceleration compared to the currently announced plan.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
October 29 2021<\/div>\n

Genomtec submits Prospectus to the Polish Financial Supervision Authority <\/h3>\n
Genomtec today filed with the Polish Financial Supervision Authority (KNF) a prospectus prepared in connection with the planned transfer of the Company’s listing to the Warsaw Stock Exchange (WSE) main market. The Company’s main motivation for the transfer is to increase its visibility and gain access to a larger group of long-term investors, including foreign ones.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
October 28 2021<\/div>\n

Genomtec secures fifth patent for its invention<\/h3>\n
Genomtec has received notification from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) that it has received patent protection for its invention, which is a contactless heating and detection technology that can be used not only in genetic research, as in the case of patent No. 235210 held by the Company, but also in any other type of devices or control systems designed outside the medical industry. This is the fifth patent received by Genomtec since the Company’s inception and the third issued by URPL.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 21 2021<\/div>\n

Genomtec\u00ae receives notice of allowance on the granting of its patent by the Japan Patent Office<\/h3>\n
Genomtec has received a notice of allowance from the Japan Patent Office (JPO) granting the Company patent protection for the Genomtec\u00aeID device and the technology invented by Genomtec SA. The invention with the new patent protection covers the key technical solutions related to the proprietary contactless heating and temperature detection system developed for POCT platforms, including Genomtec\u00ae ID.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 25 2021<\/div>\n

Genomtec has filed a patent application for a set of primers for detecting Salmonella enterica infections, one of the most common infectious diseases among humans and animals<\/h3>\n
Company has filed a patent application for a proprietary primer set, diagnostic method and reaction mixture composition for genetic diagnosis of Salmonella enterica infections using the LAMP technique. The application was filed with the Patent Office of the Republic of Poland. The detection technology developed by Genomtec is faster and less expensive than those currently used on the market.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 16 2021<\/div>\n

Genomtec intends to move to the Main Market of the Warsaw Stock Exchange (WSE)<\/h3>\n
Genomtec S.A. has expressed its intention to seek a transfer of the Company’s listing from the alternative stock exchange of NewConnect to the main market of the Warsaw Stock Exchange (WSE). Accordingly, the Board of Directors has convened an Extraordinary General Meeting for September 13 this year, for Genomtec shareholders to pass a resolution authorizing the Board of Directors to carry out the necessary actions to transfer the listing of the Company’s shares. The listing on WSE is not planned to come with new issue of shares. The main objective of the Board is to access a larger group of long-term investors, including international ones.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 12 2021<\/div>\n

Genomtec’s flagship solution enters critical development phase. Company summarizes second quarter activities<\/h3>\n
Genomtec S.A. has published a report for the second quarter of 2021 containing financial results and a summary of the most important activities during this period, including a description of the progress of the Company’s flagship solution, which is a rapid mobile diagnostic platform – Genomtec ID. During the second quarter, the Company adapted the Genomtec ID prototype to pre-production and conducted EMC testing. The Company continued the development of the molecular diagnostic panels. Genomtec also received patent protection for a set of primers for duplicating the nucleotide sequence of Borrelia burgdorferi, the bacterium that causes Lyme disease, and filed another important patent application in the area of MRSA – infection of the body with methicillin-resistant Staphylococcus aureus. This is the third patent that the Company has obtained since commencing its operations.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 6 2021<\/div>\n

Genomtec receives ISO 13485 certification completing another essential step in the Genomtec ID project<\/h3>\n
Genomtec SA has been certified in accordance to ISO 13485 standard for its quality management system compliance via audits carried out by T\u00dcV Rheinland – a prestigious, independent Certification Body. The certificate was awarded for the design and development of IVD devices for the detection of pre-determined pathogens and confirms Company\u2019s top commitment towards quality development of medical devices. Obtained certification is necessary for the purpose of Genomtec ID mobile genetic diagnostic platform registration that is planned for mid-2022.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
July 26 2021<\/div>\n

Global experts on the Genomtec Scientific Advisory Board<\/h3>\n
The Company has appointed a Scientific Advisory Board consisting of global experts in healthcare systems management and technology. The Board’s mission is to support Genomtec in the further development of the Company’s innovative technology, its business and products clinical development. Current appointees to the Scientific Advisory Board include: Eric Garnier – with 35 years of experience in the medical industry, and Prof. Krishnendu Chakrabarty – winner of numerous scientific awards, and holder of 18 patents in the US market, specializing in the area of microfluidic techniques. It is predicted for the future to extend appointees to the Scientific Advisory Board for specialists in the field of diagnostics and treatment of infectious diseases.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 24 2021<\/div>\n

Genetic tests Genomtec SARS-CoV-2 Duo Kit (Cat. no.: GA00B) and Direct-RT-LAMP Kit (Cat. no.: GA00C) detect multiple virus lineages<\/h3>\n
As part of our standard product surveillance and assurance strategy, and also due to growing concerns on ability of IVD tests to recognize newly appearing SARS-CoV-2 variants, Genomtec conducted bioinformatic (in-silico) as well as the wet lab analysis of its products, Genomtec\u00ae SARS-CoV-2 EvaGreen\u00ae RT-LAMP CE-IVD Duo Kit (RT-LAMP Duo) and Genomtec\u00ae SARS-CoV-2 EvaGreen\u00ae Direct-RT-LAMP CE-IVD Kit (Direct).<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 23 2021<\/div>\n

Jaros\u0142aw Oleszczuk changes his scope of involvement in Genomtec transiting from Management Board to Supervisory Board<\/h3>\n
The company announced in the draft resolution of the Extraordinary General Meeting of Shareholders convened on July 20 this year, with the intention to appoint Dr. Jaros\u0142aw Oleszczuk to the Supervisory Board of Genomtec. At the time of publication of the draft resolution announcement by Genomtec Dr. Jaros\u0142aw Oleszczuk resigned from his current position of a Member of the Management Board with an effect on June 23 this year. From August 1 this year the CBO role will be assigned to by Charudutt Shah – a newly appointed Member of the Genomtec\u2019s Management Board.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 31 2021<\/div>\n

Genomtec strengthens the management board – Charudutt Shah joins the company<\/h3>\n
Genomtec SA announced that Charudutt Shah is joining the board. The newly appointed member of the Genomtec board is a senior executive with many years of international experience, incl. in the area of business development, marketing and sales management and strategic planning in the clinical genetic diagnosis sector. He will start work at Genomtec on August 1, 2021.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 25 2021<\/div>\n

Genomtec expands patient group in the additional comparative study of its COVID-19 test directly from saliva<\/h3>\n
The company will conduct additional comparative study of its test detecting SARS-CoV-2 directly from saliva sample utilizing the Direct-RT-LAMP technology against the reference RT-PCR method, executed via the agreement signed with the Cellgen Molecular Pathology Center (NZOZ Aurimed). The comparative study will be performed in the Cellgen\u2019s laboratory. The acquired clinical data will enrich positive results obtained from currently running clinical validation research at the Central Clinical Hospital of the Ministry of Interior and Administration, which enabled market authorisation of the product in the European Union.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 17 2021<\/div>\n

Genomtec launches the world’s first genetic diagnostic test for the detection of SARS-CoV-2 directly from a saliva sample<\/h3>\n
Genomtec SA has registered and launched in the European Union market the Genomtec\u00ae SARS-Cov-2 EvaGreen\u00ae Direct-RT-LAMP CE-IVD Kit (RT-LAMP Direct Kit), which enables identification of SARS-CoV-2 infection from the patient’s saliva. The innovative test will provide patients with greater comfort due to lack of swabbing, e.g. from the nasopharynx. The possibility of testing using saliva will also reduce the risk of virus\u2019 contraction by the personnel collecting the sample, additionally sampling does not require specialized skills.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 10 2021<\/div>\n

Genomtec receives the third patent based on the LAMP technique<\/h3>\n
The company has been granted a patent protection from the Patent Office of the Republic of Poland for a set of primers amplifying Borrelia burgdorferi\u2019s nucleotide sequence , i.e. the bacteria causing Lyme disease. The patent developed by the Genomtec team covers the method of detecting Borrelia burgdorferi, the method of Lyme disease diagnosis, and a diagnostic kit for Lyme disease. It is the second patent granted by the Patent Office of the Republic of Poland and the third patent received by the Company. Currently, Genomtec has got pending twenty patent applications worldwide.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
April 30 2021<\/div>\n

DCM DOLMED S.A. is becoming the reference laboratory for products offered by Genomtec S.A.<\/h3>\n
The company signed an agreement with the Lower Silesian Medical Center DOLMED S.A. \u2013 the leader of multidisciplinary healthcare provision in Wroclaw and Lower Silesia. The cooperation\u2019s aim is to commence offering Genomtec\u2019s products and services for patients in DCM DOLMED\u2019s genetic diagnostic laboratory utilizing RT-LAMP technique for SARS-CoV-2 testing using Genomtec\u00ae SARS-CoV-2 EvaGreen\u00ae RT -LAMP CE-IVD Duo-Kit (RT-LAMP Duo Kit). Due to the close cooperation of both entities DOLMED will become the reference laboratory for products offered by Genomtec S.A.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
April 22 2021<\/div>\n

Genomtec submits yet another patent application in the LAMP technology confirming implementation of its work plan dedicated to Genomtec ID<\/h3>\n
Genomtec SA filed yet another significant patent application to The Polish Patent Office, Republic of Poland. The patent application concerns the proprietary set of primers, the diagnostic method and the reaction mixture composition for genetic diagnosis of MRSA (methicillin-resistant staphylococcus aureus) in the LAMP technique. The assay is part of the systemic infections diagnostic panel planned for Genomtec ID – a mobile genetic testing platform dedicated for doctor’s office, ambulance, airport or pharmacy.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div> <\/div>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n\n
<\/a>
\n

Current Reports (translated reports do not inlcude technical ones)<\/h2> <\/div>\n<\/section>\n\n
\n
\n
\n
\n
\n 2026<\/a>2025<\/a>2024<\/a>2023<\/a>2022<\/a>2021<\/a> <\/div>\n <\/div>\n
\n
\n
<\/div>
\n
February 12 2026<\/div>\n

Current Report No 6\/2026<\/h3>\n
Information on the commencement of preparatory activities related to the planned testing of Genomtec technology in Asia<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
December 11 2025<\/div>\n

Current Report No 42\/2025<\/h3>\n
Receipt of a decision from the United States Patent Office to grant patent protection<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
October 15 2025<\/div>\n

Current Report No 41\/2025<\/h3>\n
Receipt of a decision from the European Patent Office to grant a European patent<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 25 2025<\/div>\n

Current Report No 40\/2025<\/h3>\n
Receipt of a decision from the European Patent Office to grant a European patent<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 15 2025<\/div>\n

Current Report No 39\/2025<\/h3>\n
Receiving a decision from the Patent Office in Japan to grant patent protection<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 15 2025<\/div>\n

Current Report No 38\/2025<\/h3>\n
Adoption by the Management Board of the Warsaw Stock Exchange of a resolution on the admission and introduction to exchange trading on the WSE Main Market of series I ordinary bearer shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 11 2025<\/div>\n

Current Report No 37\/2025<\/h3>\n
Grant of shares as part of a conditional increase in share capital<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 14 2025<\/div>\n

Current Report No 35\/2025<\/h3>\n
Grant of shares as part of a conditional increase in share capital<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 1 2025<\/div>\n

Current Report No 35\/2025<\/h3>\n
Receipt of a decision to grant patent protection from the Patent Office in Japan<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
July 30 2025<\/div>\n

Current Report No 34\/2025<\/h3>\n
Appointment of a new Member of the Management Board of GENOMTEC SA<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
July 11 2025<\/div>\n

Current Report No 33\/2025<\/h3>\n
List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of Genomtec SA<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
July 11 2025<\/div>\n

Current Report No 32\/2025<\/h3>\n
Content of resolutions adopted by the Extraordinary General Meeting of Genomtec SA on July 11, 2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 13 2025<\/div>\n

Current Report No 31\/2025<\/h3>\n
Convening the Extraordinary General Meeting Genomtec SA as of July 11, 2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 6 2025<\/div>\n

Current Report No 30\/2025<\/h3>\n
List of shareholders holding at least 5% of the votes at the Annual General Meeting of Genomtec SA<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 5 2025<\/div>\n

Current Report No 29\/2025<\/h3>\n
Content of resolutions adopted by the Annual General Meeting of Genomtec SA on June 5, 2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 23 2025<\/div>\n

Current Report No 28\/2025<\/h3>\n
Completion of documentation for the Annual General Meeting Genomtec SA<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 23 2025<\/div>\n

Current Report No 27\/2025<\/h3>\n
Notification of a change in the ownership of the Company’s shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 20 2025<\/div>\n

Current Report No 26\/2025<\/h3>\n
Notification of transactions involving the Company’s shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 20 2025<\/div>\n

Current Report No 25\/2025<\/h3>\n
Notification of a change in the ownership of the Company’s shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 9 2025<\/div>\n

Current Report No 24\/2025<\/h3>\n
Convening the Annual General MeetingGenomtec SA as of June 5, 2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 9 2025<\/div>\n

Current Report No 23\/2025<\/h3>\n
Update of information on the establishment of subsidiaries by Genomtec SA in connection with adaptation to the requirements of the M&A process<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 26 2025<\/div>\n

Current Report No 22\/2025<\/h3>\n
Notification of transactions performed on the Company’s shares<\/div>
Download<\/a><\/div><\/div>
Appendix to ESPI 22\/2025 Report<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 26 2025<\/div>\n

Current Report No 21\/2025<\/h3>\n
Update of information on the implementation of Genomtec’s strategic development directions \u2013 Establishment of special purpose vehicles as part of the change in the Company’s organizational structure related to adaptation to the requirements of the M&A process<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 21 2025<\/div>\n

Current Report No 20\/2025<\/h3>\n
Notification of change in the ownership of shares in the Company<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 19 2025<\/div>\n

Current Report No 19\/2025<\/h3>\n
Registration of the increase in share capital and changes to the Company’s articles of association in the register of entrepreneurs of the National Court Register<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 13 2025<\/div>\n

Current Report No 18\/2025 – Correction<\/h3>\n
Correction of current report no. 18\/2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 12 2025<\/div>\n

Current Report No 18\/2025<\/h3>\n
List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of Genomtec S.A. on March 12, 2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 12 2025<\/div>\n

Current Report No 17\/2025<\/h3>\n
Information on the content of resolutions adopted by the Extraordinary General Meeting of Genomtec SA on March 12, 2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 10 2025<\/div>\n

Current Report No 16\/2025<\/h3>\n
Submission by a shareholder of a draft resolution regarding a matter included in the agenda of the Extraordinary General Meeting of the Company convened for March 12, 2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
March 10 2025<\/div>\n

Current Report No 15\/2025<\/h3>\n
Conclusion of an additional agreement to the investment agreement of 12 February 2025<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 28 2025<\/div>\n

Current Report No 14\/2025<\/h3>\n
Completion of the public offering of the existing shares of the Company conducted by the Shareholder and determination of the final number of new issue shares of series P that the Company will be obliged to offer for acquisition by the Shareholder<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 27 2025<\/div>\n

Current Report No 13\/2025<\/h3>\n
Notification of an entity indirectly holding shares in the Company about a change in the ownership of shares in the Company<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 27 2025<\/div>\n

Current Report No 12\/2025<\/h3>\n
Notification of a shareholder about a change in the ownership of the Company’s shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 24 2025<\/div>\n

Current Report No 11\/2025<\/h3>\n
Conclusion of an agreement on determining the number and sale price of existing shares in the Company as part of a public offering conducted by the Shareholder<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 17 2025<\/div>\n

Current Report No 10\/2025<\/h3>\n
Conclusion of an agreement with an international consulting company<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 13 2025<\/div>\n

Current Report No 9\/2025<\/h3>\n
Notification of a shareholder about a change in the ownership of the Company’s shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 13 2025<\/div>\n

Current Report No 8\/2025<\/h3>\n
Notification of a shareholder about a change in the ownership of the Company’s shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 13 2025<\/div>\n

Current Report No 7\/2025<\/h3>\n
Commencement of the public offering of the Company’s existing shares by the Shareholder in the accelerated bookbuilding procedure<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 12 2025<\/div>\n

Current Report No 6\/2025<\/h3>\n
Notification of transactions performed on the Company’s shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 12 2025<\/div>\n

Current Report No 5\/2025<\/h3>\n
Information on Convening the Extraordinary General Meeting of Genomtec S.A. along with the Content of Draft Resolutions.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 12 2025<\/div>\n

Current Report No 4\/2025<\/h3>\n
Conclusion of an Investment Agreement for the Purpose of Raising Equity Financing by the Company.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
January 28 2025<\/div>\n

Current Report No 3\/2025<\/h3>\n
Filing of a second patent application for an oncology project<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
December 14 2024<\/div>\n

Current Report No 29\/2024<\/h3>\n
Changes in the organizational structure of the Company related to adaptation to the requirements of the M&A process and the strategic directions of development of Genomtec<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
October 15 2024<\/div>\n

Current Report No 28\/2024<\/h3>\n
Correction of a notification from a Member of the Management Board pursuant to Article 19 section 1 of the MAR Regulation<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
October 11 2024<\/div>\n

Current Report No 27\/2024<\/h3>\n
Notification received from a Member of the Management Board pursuant to Article 19 section 1 of the MAR Regulation regarding the acquisition of Genomtec shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
October 8 2024<\/div>\n

Current Report No 26\/2024<\/h3>\n
Notification received from the President of the Management Board pursuant to Article 19 section 1 of the MAR Regulation regarding the acquisition of Genomtec shares<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 25 2024<\/div>\n

Current Report No 25\/2024<\/h3>\n
Information about recognition by NCBR of the grant received by the Company as implemented<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
July 24 2024<\/div>\n

Current Report No 24\/2024<\/h3>\n
Dismissal of a Member of the Management Board of Genomtec SA<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
March 21 2023<\/div>\n

Current Report No 4\/2023<\/h3>\n
Continuation of the review of strategic options – distribution of funds from the potential sale of technology<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 9 2023<\/div>\n

Current Report No 6<\/h3>\n
Receipt of the decision on granting patent protection for the invention in the territory of USA<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
January 10 2023<\/div>\n

Current Report No 2<\/h3>\n
Obtaining a valuation of the portfolio of Genomtec’a intellectual property rights<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
December 13 2022<\/div>\n

Current Report No 28<\/h3>\n
Completion of the Company’s financing phase and conclusion of loan agreements<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 30 2022<\/div>\n

Current Report No 27<\/h3>\n
Concluding an agreement with a transaction advisor<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 15 2022<\/div>\n

Current Report No 24<\/h3>\n
Receipt of the decision on granting patent protection for the invention in the territory of Brazil<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 7 2022<\/div>\n

Current Report No 22<\/h3>\n
Commencement of review of strategic options and signing of contract to perform IP valuation of the company<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 29 2022<\/div>\n

Current Report No 16<\/h3>\n
Obtaining patent protection for an invention from the European Patent Office<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 27 2022<\/div>\n

Current Report No 15<\/h3>\n
Signing a commercial agreement for distribution of Genomtec\u00aeID<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 8 2022<\/div>\n

Current Report No 12<\/h3>\n
Market authorisation for sales of Genomtec\u00ae ID<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
April 29 2022<\/div>\n

Current Report No 6<\/h3>\n
Signing a commercial agreement to sell Genomtec\u00ae ID<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
February 14 2022<\/div>\n

Current Report No 3<\/h3>\n
Commencement of comparative research<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
January 20 2022<\/div>\n

Current Report No 2<\/h3>\n
Receipt of the decision on granting patent protection from the European Patent Office<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
January 12 2022<\/div>\n

Current Report No 1<\/h3>\n
Start of pilot production of analysers Genomtec\u00aeID in the UK<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div>
<\/div>
\n
December 24 2021<\/div>\n

Current Report No 31<\/h3>\n
Acceleration of the Genomtec\u00ae ID platform commercialization and signing up loan agreements in connection to financing of the fast-tracked project activities<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 29 2021<\/div>\n

Current Report No 30<\/h3>\n
Patent filing application for a method of heat transfer and its measurement with the UK Intellectual Property Office (UK IPO)<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 19 2021<\/div>\n

Current Report No 29<\/h3>\n
Receipt of the decision on granting patent protection for the proprietary set of primers, diagnostic method, and the use of primer set for HPV infection detection to genetically diagnose HPV16 (Human papillomavirus type 16) in the territory of Republic of Poland<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
November 3 2021<\/div>\n

Current Report No 27<\/h3>\n
Planned acceleration of the Genomtec\u00aeID platform commercialization process<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
October 29 2021<\/div>\n

Current Report No 26<\/h3>\n
Submission to the Financial Supervision Authority of an application for approval of the prospectus of Genomtec S.A.<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
October 28 2021<\/div>\n

Current Report No 25<\/h3>\n
Receipt of the decision on granting patent protection for the temperature control invention in the territory of Republic of Poland<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
September 21 2021<\/div>\n

Current Report No 23<\/h3>\n
Receipt of the decision on granting patent protection for the invention in the territory of Japan<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 25 2021<\/div>\n

Current Report No 21<\/h3>\n
Patent application filed for the proprietary set of primers, diagnostic method, and the reaction mixture composition to genetically diagnose Salmonella enterica infections in LAMP technique<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
August 6 2021<\/div>\n

Current Report No 18<\/h3>\n
T\u00dcV Rheinland has issued ISO 13485 certificate for Genomtec<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
July 7 2021<\/div>\n

Current Report No 16<\/h3>\n
Patent filing application for the proprietary set of primers, diagnostic method and the reaction mixture composition to genetically diagnose Neisseria Meningitidis in LAMP technique<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 23 2021<\/div>\n

Current Report No 13<\/h3>\n
A contract signed with specialist clinical center based in Gliwice to execute part of the comparative study (referenced to the Real-Time RT-PCR method) validating the SARS-CoV-2 infection detection kit based on the saliva Direct-RT-LAMP technology<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 25 2021<\/div>\n

Current Report No 11<\/h3>\n
A contract signed with Cellgen Molecular Pathology Centre, Aurimed Private Healthcare Trust to execute part of the comparative study (referenced to the Real-Time RT-PCR method) validating the SARS-CoV-2 infection detection kit based on the saliva Direct-RT-LAMP technology<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 17 2021<\/div>\n

Current Report No 10<\/h3>\n
Market authorisation for sales of Genomtec\u00ae SARS-CoV-2 EvaGreen\u00ae Direct-RT-LAMP CE-IVD Kit<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
May 10 2021<\/div>\n

Current Report No 9<\/h3>\n
Patent protection has been granted for a set of primers for amplifying the nucleotide sequence of Borrelia burgdorferi, a method for detecting Borrelia burgdorferi, a method for diagnosing Lyme disease and a kit for diagnosing Lyme disease<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
June 30 2021<\/div>\n

Current Report No 8<\/h3>\n
Signatory of a cooperation agreement leading to opening of a diagnostic laboratory that utilizes Issuer\u2019s products and know-how<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div>
<\/div>
\n
April 22 2021<\/div>\n

Current Report No 6<\/h3>\n
Patent filing application for the proprietary set of primers, diagnostic method and the reaction mixture composition to genetically diagnose MRSA (methicillin-resistant staphylococcus aureus) in LAMP technique<\/div>
Download<\/a><\/div><\/div><\/div>\n <\/div><\/div><\/div> <\/div>\n <\/div>\n <\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":33104,"parent":0,"menu_order":13,"comment_status":"closed","ping_status":"closed","template":"template-investycja.php","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-34623","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nPress Releases & News - Genomtec<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/genomtec.com\/en\/press-releases-news\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Press Releases & News - Genomtec\" \/>\n<meta property=\"og:url\" content=\"https:\/\/genomtec.com\/en\/press-releases-news\/\" \/>\n<meta property=\"og:site_name\" content=\"Genomtec\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-19T10:22:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/genomtec.com\/wp-content\/uploads\/2021\/03\/genomtecgfx_6.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1902\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/genomtec.com\/#website\",\"url\":\"https:\/\/genomtec.com\/\",\"name\":\"Genomtec\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/genomtec.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/genomtec.com\/en\/press-releases-news\/#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/genomtec.com\/wp-content\/uploads\/2021\/03\/genomtecgfx_6.jpg\",\"contentUrl\":\"https:\/\/genomtec.com\/wp-content\/uploads\/2021\/03\/genomtecgfx_6.jpg\",\"width\":1902,\"height\":250},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/genomtec.com\/en\/press-releases-news\/#webpage\",\"url\":\"https:\/\/genomtec.com\/en\/press-releases-news\/\",\"name\":\"Press Releases & News - Genomtec\",\"isPartOf\":{\"@id\":\"https:\/\/genomtec.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/genomtec.com\/en\/press-releases-news\/#primaryimage\"},\"datePublished\":\"2021-06-27T18:34:26+00:00\",\"dateModified\":\"2026-03-19T10:22:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/genomtec.com\/en\/press-releases-news\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/genomtec.com\/en\/press-releases-news\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/genomtec.com\/en\/press-releases-news\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Press Releases & News\"}]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Press Releases & News - Genomtec","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/genomtec.com\/en\/press-releases-news\/","og_locale":"en_US","og_type":"article","og_title":"Press Releases & News - Genomtec","og_url":"https:\/\/genomtec.com\/en\/press-releases-news\/","og_site_name":"Genomtec","article_modified_time":"2026-03-19T10:22:25+00:00","og_image":[{"width":1902,"height":250,"url":"https:\/\/genomtec.com\/wp-content\/uploads\/2021\/03\/genomtecgfx_6.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebSite","@id":"https:\/\/genomtec.com\/#website","url":"https:\/\/genomtec.com\/","name":"Genomtec","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/genomtec.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/genomtec.com\/en\/press-releases-news\/#primaryimage","inLanguage":"en-US","url":"https:\/\/genomtec.com\/wp-content\/uploads\/2021\/03\/genomtecgfx_6.jpg","contentUrl":"https:\/\/genomtec.com\/wp-content\/uploads\/2021\/03\/genomtecgfx_6.jpg","width":1902,"height":250},{"@type":"WebPage","@id":"https:\/\/genomtec.com\/en\/press-releases-news\/#webpage","url":"https:\/\/genomtec.com\/en\/press-releases-news\/","name":"Press Releases & News - Genomtec","isPartOf":{"@id":"https:\/\/genomtec.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/genomtec.com\/en\/press-releases-news\/#primaryimage"},"datePublished":"2021-06-27T18:34:26+00:00","dateModified":"2026-03-19T10:22:25+00:00","breadcrumb":{"@id":"https:\/\/genomtec.com\/en\/press-releases-news\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/genomtec.com\/en\/press-releases-news\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/genomtec.com\/en\/press-releases-news\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Press Releases & News"}]}]}},"_links":{"self":[{"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/pages\/34623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/comments?post=34623"}],"version-history":[{"count":102,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/pages\/34623\/revisions"}],"predecessor-version":[{"id":40480,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/pages\/34623\/revisions\/40480"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/media\/33104"}],"wp:attachment":[{"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/media?parent=34623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}